Identification of MCM4 and PRKDC as new regulators of osteosarcoma cell dormancy based on 3D cell cultures.

3D spheroids Cell dormancy Osteosarcoma Quiescency Transcriptomic profile

Journal

Biochimica et biophysica acta. Molecular cell research
ISSN: 1879-2596
Titre abrégé: Biochim Biophys Acta Mol Cell Res
Pays: Netherlands
ID NLM: 101731731

Informations de publication

Date de publication:
10 Jan 2024
Historique:
received: 07 09 2023
revised: 15 12 2023
accepted: 03 01 2024
medline: 13 1 2024
pubmed: 13 1 2024
entrez: 12 1 2024
Statut: aheadofprint

Résumé

Dormancy is a potential way for tumors to develop drug resistance and escape treatment. However, the mechanisms involved in cancer dormancy remain poorly understood. This is mainly because there is no in vitro culture model making it possible to spontaneously induce dormancy. In this context, the present work proposes the use of three-dimensional (3D) spheroids developed from osteosarcoma cell lines as a relevant model for studying cancer dormancy. MNNG-HOS, SaOS-2, 143B, MG-63, U2OS and SJSA-1 cell lines were cultured in 3D using the Liquid Overlay Technique (LOT). Dormancy was studied by staining cancer cells with a lipophilic dye (DiD), and long-term DiD

Identifiants

DOI: 10.1016/j.bbamcr.2024.119660 PMID: 38216092
pubmed: 38216092
pii: S0167-4889(24)00003-X
doi: 10.1016/j.bbamcr.2024.119660
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

119660

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Atlantic Bone Screen paid the salary of Camille Jubelin. Dominique Heymann is one of the founder and stakeholder of Atlantic Bone Screen.

Auteurs

Camille Jubelin (C)

Nantes Université, CNRS, US2B, UMR 6286, 44000 Nantes, France; Institut de Cancérologie de l'Ouest, Tumor Heterogeneity and Precision Medicine Lab., 44805 Saint-Herblain, France; Atlantic Bone Screen, 44800 Saint-Herblain, France.

Javier Muñoz-Garcia (J)

Nantes Université, CNRS, US2B, UMR 6286, 44000 Nantes, France; Institut de Cancérologie de l'Ouest, Tumor Heterogeneity and Precision Medicine Lab., 44805 Saint-Herblain, France.

Emilie Ollivier (E)

Institut de Cancérologie de l'Ouest, Tumor Heterogeneity and Precision Medicine Lab., 44805 Saint-Herblain, France.

Denis Cochonneau (D)

Institut de Cancérologie de l'Ouest, Tumor Heterogeneity and Precision Medicine Lab., 44805 Saint-Herblain, France.

François Vallette (F)

Institut de Cancérologie de l'Ouest, Tumor Heterogeneity and Precision Medicine Lab., 44805 Saint-Herblain, France; Nantes Université, INSERM, CRCI(b)NA, UMR1307, 44000 Nantes, France.

Marie-Françoise Heymann (MF)

Nantes Université, CNRS, US2B, UMR 6286, 44000 Nantes, France; Institut de Cancérologie de l'Ouest, Tumor Heterogeneity and Precision Medicine Lab., 44805 Saint-Herblain, France.

Lisa Oliver (L)

Nantes Université, INSERM, CRCI(b)NA, UMR1307, 44000 Nantes, France; CHU de Nantes, Nantes, France.

Dominique Heymann (D)

Nantes Université, CNRS, US2B, UMR 6286, 44000 Nantes, France; Institut de Cancérologie de l'Ouest, Tumor Heterogeneity and Precision Medicine Lab., 44805 Saint-Herblain, France; Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, UK. Electronic address: dominique.heymann@univ-nantes.fr.

Classifications MeSH